(SUMM.L) Summit Corporation PLC Buy/Sell

Summit Corporation plc

("Summit plc" or "the Company")

DIRECTOR SHARE DEALINGS

Oxford, UK, 05 March 2010, Summit (AIM: SUMM), a leading UK drug discovery company with a portfolio of partnered drug programmes and a proprietary second generation iminosugar technology platform, has been notified that Professor Stephen Davies, Non-executive Director and co-founder of the Company, has today purchased 50,000 Ordinary shares of one pence each at a price of 4.69 pence per share.

This purchase is in addition to Professor Davies' purchase of 400,000 Ordinary shares in November 2009 and a subscription for 1,000,000 Ordinary shares as part of the successful fundraising that completed in December 2009.

Professor Davies now holds a total of 7,658,748 shares representing 4.61% of the issued share capital .

Summit Corporation plc

("Summit plc" or "the Company")

DIRECTOR AND PDMR SHARE DEALINGS

Oxford, UK, 05 March 2010, Summit (AIM: SUMM), a leading UK drug discovery company with a portfolio of partnered drug programmes and a proprietary second generation iminosugar technology platform, has today been notified about the following purchase of One pence Ordinary Shares in Summit by the Executive management of the Company:
Name Position Shares Purchased Date Price per share Current % of Issued Share
of Holding Capital
purchase
Steven Lee, PhD Chief Executive 50,000 05/03/2010 4.70p 2,432,492 1.46%
Officer
Raymond Spencer, ACA Chief Financial 200,000 04/03/2010 4.67p 900,000 0.54%
Officer
Richard Storer, DPhil Chief Scientific 60,000 05/03/2010 4.70p 576,229 0.35%
Officer

Today's purchase by Summit's Chief Executive Officer, Dr Steven Lee, follows his recent purchase of 200,000 Ordinary shares in November 2009 and a subscription for 2,000,000 Ordinary shares as part of the successful fund raising that completed in December 2009.

The Company's Chief Financial Officer, Mr Raymond Spencer, also purchased a total of 300,000 Ordinary shares between October and November 2009, and Summit's Chief Scientific Officer, Dr Richard Storer, purchased 100,000 Ordinary shares in November 2009. In addition, Dr Storer and Mr Spencer each subscribed for 400,000 Ordinary shares as part of the December 2009 fundraising.

Following today's share purchases, the total holdings of the Directors and PDMR of the Company is now 7.9% of the issued share capital of the Company.

Summit Corporation plc

("Summit" or "the Company")

PRE-CLOSE TRADING UPDATE

Oxford, UK, 24 February 2010, Summit (AIM: SUMM), a leading UK drug discovery company with a portfolio of partnered drug programmes and a proprietary iminosugar technology platform, announces a pre-close trading update ahead of its final results for the year ended 31 January 2010. Summit anticipates announcing its final results in early May 2010.

The Board are pleased with the recent progress of the Company in spite of the challenging economic climate. The Company is now focussed on developing its iminosugar platform having disposed of non-core businesses and having made significant reductions in its cash burn. These changes enabled the Company to successfully complete a fund-raise in December 2009 and the Board now looks forward with confidence to reaching a number of key milestones from existing partnered programmes and the signing of new platform or programme based deals.

Strong Financial Position

In December 2009, Summit raised £5.4 million through a Placing and Open Offer to current and new investors which, excluding milestone payments from existing and potential future deals will provide the business with cash resources until at least December 2011. This investment ensures the Company is funded well beyond the point where it anticipates receiving significant milestone payments from our partners and will accelerate the development of Summit's innovative iminosugar technology platform.

Summit had a cash position of £6.0 million on 31 January 2010.

£2.2 million Wellcome Trust Grant

In addition in December 2009, Summit was awarded a grant worth up to £2.2
million from the Wellcome Trust to fund the development of the Company's C.
difficile infectious disease programme. C. difficile is a life

threatening pathogen for which current therapy options are limited. In 2008 in the UK, C. difficile was responsible for over three times more deaths than the MRSA superbug. Summit has identified a novel class of compounds that are effective against C. difficile and the grant will completely fund their development until 2012 at which time the Company would expect to have a compound ready to enter human clinical trials. The Company drew down the first instalment of the grant of £550,000 in January 2010.

The C. difficile programme has significant commercial potential and the Company will seek to capitalise on this as the programme advances. Furthermore, the Wellcome Trust funding endorses the scientific innovation and expertise that exists within Summit.

DMD Programme Enters Clinical Trials The Company received a further boost in January 2010, when BioMarin Pharmaceuticals Inc. announced that it had initiated a Phase 1 clinical study of SMT C1100 (also known as BMN 195). Discovered by Summit scientists, SMT C1100 is a small molecule utrophin upregulator for the treatment of Duchenne muscular dystrophy (DMD), a fatal genetic disease for which there is currently no cure. The programme was licensed to BioMarin in July 2008 and Summit is eligible to receive significant development and regulatory milestone payments and tiered royalties rising to a low-teen percentage over this potentially disease modifying medicine. BioMarin has indicated that initial top-line results from this Phase I trial are expected in Q3 2010.

New medicines from Iminosugars

Summit's major R&D focus is on developing new medicines from its proprietary iminosugar drug discovery technology platform. This technology platform is attracting increasing levels of interest and Summit is exploring potential collaborations with a number of pharmaceutical and biotechnology companies to
investigate its platform in a range of major therapy areas. The Board believes

the next 12 months will be an important period in the development of this innovative technology.

Internally, Summit is currently focusing its research activities in the multi-billion dollar therapeutic areas of diabetes and infectious diseases. This includes SMT 14224, which is being developed as a new treatment for type II diabetes with data on this compound indicating that it potentially works via a new mechanism of action. Initial marketing of SMT 14224 has resulted in interest being shown from several leading pharmaceutical companies and Summit is investing a portion of the new finance into studies designed to add further value to this programme.

Dr Steven Lee, PhD, Chief Executive Officer of Summit commented:

"I am pleased that Summit has emerged from a challenging year as a leaner and more focussed business. Following the pleasing level of support received from current and new investors, I believe the business is now well positioned to deliver shareholder value from our set of novel and increasingly valuable assets."